ClinicalTrials.gg
RecruitingNCT06211868RESETUpdated Oct 15, 2024

Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

An observational study in Cardiovascular Diseases, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease, sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by National University Hospital, Singapore · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
40 Years to 70 Years
Sex
All
01

Study summary

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

02

Conditions studied

  • Cardiovascular Diseases
  • Metabolic Syndrome
  • Non-Alcoholic Fatty Liver Disease
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

National University Hospital, Singapore is the lead sponsor of 455 studies on the registry; 100 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

South-East Asian population aged 40-70 years with no prior manifest atherosclerotic cardiovascular disease (ACSVD).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 40-70 years old
  • ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher

Exclusion criteria

Exclusion Criteria:

  • Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
  • Limited
  • Other ongoing unstable medical conditions
  • Pregnant women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Observational cohort
  • Randomised cohort

    Behavioral: Digital wearable and AI-human symbiotic lifestyle intervention

Interventions

  • BehavioralDigital wearable and AI-human symbiotic lifestyle intervention

    Digital wearable and AI-human symbiotic lifestyle intervention

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular event

    Composite of cardiac death, non-fatal myocardial infarction, resuscitated cardiac arrest, non-fatal ischemic stroke, congestive heart failure, coronary revascularization

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • NUS
    Singapore, Singapore
    Recruiting
    • Hayang Yang, PhD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2029, 66 months after the start.

Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 66 months is close to that.

Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Jan 18, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Sep 1, 2029
CompletionEst.
Sep 1, 2030
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06211868
Responsible party
Sponsor
First posted
Jan 18, 2024
Start date
Mar 1, 2024
Primary completion
Sep 1, 2029 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Oct 15, 2024

Study contacts

Hayang Yang, PhD
Contact
h.yang@nus.edu.sg
+6582810448

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion